Abstracts | 81 of 10000 lux would have much less impact on Indian subjects. 2. Ethnicity -in both studies the subjects were born and spent considerable time in their own respective country. 3. Cultural variations in the food consumed usually by the subjects in respective countries. 
Abstract Accumulating evidence suggests that there is a bidirectional association between major depressive disorder (MDD) and type 2 diabetes mellitus. To elucidate impaired glycemic control in MDD in more detail, we conducted the five-hour oral glucose tolerance test (OGTT) in patients with MDD. Methods: Twenty-five outpatients with DSM-IV MDD were recruited into the study along with 28 controls. A 5-hour OGTT using 75 g of glucose was employed to assess glucose regulation based on blood samples. Samples were drawn nine times and blood pressure, heart rate and body temperature were also measured at the same time. Results: Patients with MDD had a higher impaired glucose tolerance (IGT) rate at 52% versus 32% among the controls. MDD patients exhibited significantly lower insulinogenic index (P = 0.043) and disposition index (P = 0.020) than controls. The areas under the curve for heart rate (P = 0.017) and body temperature (P = 0.024) during the OGTT were significantly higher in MDD than in the controls. Conclusion: MDD patients exhibited hyperglycemia, initial insulin hyposecretion, and sympathetic dominance during the OGTT resulting in IGT compared to controls. Abstract Background: Subanaesthetic doses of intravenous ketamine have been shown to elicit rapid reduction in depressive symptoms and severity of suicidal ideation (SI). However, the antidepressant properties of ketamine appear to be transient. Repeated ketamine infusions may prolong the antidepressant effect. The objective of this study was to determine whether ketamine could elicit decrease in SI even in patients who do not have a reduction in depressive symptoms with prolonged treatment.
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Ketamine Exerts a Prolonged Reduction in Suicidal Ideation Independent of its Antidepressant Effects
Methods: 19 patients with treatment-resistant major depressive disorder (MDD) completed a randomized controlled trial of ketamine. Patients received 7 intravenous ketamine infusions during the study, including a single infusion during the Phase 1 double-blind crossover with midazolam (used as an active placebo), and 6 ketamine infusions administered over a two-week period during Phase 2. The primary outcome measures were pre-and post-treatment changes in depressive symptoms (using the Montgomery-Asberg Depression Rating Scale [MADRS]) and suicidal ideation (using MADRS-SI scores). Results: Patients with a 50% decrease in total MADRS scores from pre-to post-treatment were considered ketamine responders. Responders (n = 10) had a larger reduction in MADRS scores (62%) compared to nonresponders (n = 9; 17%) (p<0.001). Both groups had significant reductions in MADRS-SI scores (responders -1.9, p<0.001; nonresponders -1.6, p<0.001) and the difference in the magnitude of change in MADRS-SI scores between groups was not statistically significant (p=0.44). Conclusions: Ketamine had a direct effect on lessening suicidal ideation even in patients who failed to show a reduction in depression severity with repeated infusions. 
PS223
